CPRX Q4 2024 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$142M+28.3% YoY

Gross Profit

$120M84.7% margin

Operating Income

$63M44.3% margin

Net Income

$56M39.4% margin

EPS (Diluted)

$0.44

QoQ Revenue Growth

+10.2%

Cash Flow

Operating Cash Flow

$71M

Free Cash Flow

$71M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$851M

Total Liabilities

$124M

Stockholders' Equity

$728M

Cash & Equivalents

$518M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$142M	$111M	+28.3%
Gross Profit	$120M	$95M	+26.8%
Operating Income	$63M	$42M	+50.7%
Net Income	$56M	$35M	+60.5%

Revenue Segments

Product Revenue Net

$264M100%

License And Other Revenue

$68,0000%